Lung Cancer

HOLLYWOOD, FL—Patients receiving chemotherapy are at risk for reactivation of the hepatitis B virus (HBV), and this can have a significant negative impact on the outcomes, including death from liver failure. According to Emmy Ludwig, MD, of Memorial Sloan-Kettering Cancer Center (MSKCC), New York, one-third of the world has been exposed to HBV, “making it an enormous problem.”

Fortunately, HBV reactivation can be prevented with the prophylactic use of effective antiviral agents, for which recommendations were presented by Ludwig at the meeting.

SAN DIEGO—Stereotactic radiation appears to be highly effective and safe for treatment of patients with operable, early-stage non–small-cell lung cancer (NSCLC). In some cases, it may be an appropriate alternative surgery, resulting in fewer side effects, according to a new Japanese study presented at the 52nd annual meeting of the American Society for Radiation Oncology.

A large National Cancer Institute (NCI)–sponsored study has shown for the first time that a screening method can reduce deaths from lung cancer by detecting cancers at relatively early stages.

The National Cancer Institute (NCI) defines cancer survivors as “people who have been diagnosed with cancer and the people in their lives who are affected by their diagnosis including family members, friends, and caregivers.”

Patients with advanced non–small-cell lung cancer (NSCLC) achieved a significant increase in overall survival when tumor treating fields (TTF) therapy was added to pemetrexed every 3 weeks, according to data released by Novocure at the European Society for Medical Oncology Congress.

Lung cancer is the leading cause of cancer death in both men and women in the United States.1 It is estimated that in 2009, 219,440 men and women were diagnosed with lung cancer and 159,390 men and women died from the disease.2 From 1975 to 2001, non–small-cell lung cancer (NSCLC) 5-year survival rates have increased from 11.9% to 15.6%. These statistics are independent of sex, race, age, and stage at diagnosis, and make acutely evident that there have been few advances in the treatment of NSCLC.

Page 6 of 6
Results 51 - 58 of 58

©2019 Green Hill Healthcare Communications, LLC, an affiliate of The Lynx Group. All rights reserved.
1249 South River Road - Suite 202, Cranbury, NJ 08512